SPDR S&P China ETF Analysts See 34.69% Upside

Written by Emily J. Thompson, Senior Investment Analyst

Source: NASDAQ.COM

Updated: Apr 03 2026

0mins

LEGN+9.35%

GPCR-3.65%

VNET-2.5%

Should l Buy LEGN?

Source: NASDAQ.COM

ETF Target Price Analysis: The SPDR S&P China ETF (GXC) has an implied analyst target price of $124.19 per unit, with a current trading price of $92.21, indicating a 34.69% upside potential that reflects market optimism about the ETF's future performance.
Stock Potential Unveiled: Legend Biotech Corp (LEGN) trades at $19.14, while analysts set a target price of $60.63, suggesting a remarkable 216.78% upside, highlighting the company's strong growth potential in the biotech sector.
Structure Therapeutics Outlook: Structure Therapeutics Inc (GPCR) is priced at $53.48, with an analyst target of $109.00, indicating a potential increase of 103.81%, showcasing market expectations for its innovative drug development.
Market Confidence in VNET: VNET Group Inc (VNET) currently trades at $8.19, with an analyst target price of $16.34, reflecting a 99.55% upside, which indicates investor confidence in its future performance.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy LEGN?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on LEGN

Wall Street analysts forecast LEGN stock price to rise

11 Analyst Rating

10 Buy

1 Hold

0 Sell

Strong Buy

Current: 21.170

Low

48.00

Averages

68.10

High

90.00

Current: 21.170

Low

48.00

Averages

68.10

High

90.00

RBC Capital

Outperform

maintain

$66 -> $62

2026-03-11

Reason

RBC Capital

Price Target

$66 -> $62

AI Analysis

2026-03-11

maintain

Outperform

Reason

RBC Capital lowered the firm's price target on Legend Biotech to $62 from $66 and keeps an Outperform rating on the shares after its Q4 results. The firm sees a significant disconnect between the share price and the fundamentals of the business, the analyst tells investors in a research note. The management's execution on many aspects of the Carvykti opportunity has been strong, with impressive Overall Survival data, improving real-world safety, expanding manufacturing, and consistent double digit revenue growth, the firm adds.

Morgan Stanley

Overweight

maintain

$50 -> $49

2026-03-11

Reason

Morgan Stanley

Price Target

$50 -> $49

2026-03-11

maintain

Overweight

Reason

Morgan Stanley lowered the firm's price target on Legend Biotech to $49 from $50 and keeps an Overweight rating on the shares. The firm, which updated estimates following the company's Q4 report, awaits additional data from the CARTITUDE-5 study and the earlier-stage in vivo pipeline this year.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for LEGN

Unlock Now

About LEGN

Legend Biotech Corporation is a global biopharmaceutical company. The Company is engaged in the discovery, development, manufacturing and commercialization of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.